Fig. 1.

PRMT1 undergoes proteasomal degradation. (A–D) Cells were treated with (A) CHX (40 µg ml^–1), (B) MG132 (20 µM) or (C) E64D (20 µM) for the indicated times, and cell lysates were subjected to immunoblotting analysis with antibodies against PRMT1 and α-tubulin. The relative PRMT1 protein levels from densitometry analysis of the immunoblots were plotted and the half-life of PRMT1 was calculated as previously described (Li et al., 2017) (D). (E) Cells were transfected with indicated amounts of HA-tagged ubiquitin plasmid, and the cell lysates were immunoblotted with anti-PRMT1, HA and β-actin antibodies. The results are representative of n=3 experiments.